LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Patients with chronic lymphocytic leukemia (CLL), the most frequent B cell malignancy in western countries, develop a progressive immunosuppression, leading to diminished anti-tumor immunity. Within the last years, immune checkpoint blockade has revolutionized anti-cancer therapies....

Descripción completa

Detalles Bibliográficos
Autores principales: Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, González-Rodríguez, Ana P., Payer, Ángel R., González-García, Esther, López-Soto, Alejandro, Gonzalez, Segundo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123840/
https://www.ncbi.nlm.nih.gov/pubmed/33925565
http://dx.doi.org/10.3390/cancers13092112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123840/
https://www.ncbi.nlm.nih.gov/pubmed/33925565
http://dx.doi.org/10.3390/cancers13092112

Ejemplares similares